EUROPA Trial European trial on reduction of cardiac

  • Slides: 4
Download presentation
EUROPA Trial European trial on reduction of cardiac events with perindopril in stable coronary

EUROPA Trial European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003

EUROPA Trial 12, 218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled

EUROPA Trial 12, 218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled Perindopril § 8 mg/day § n=6, 110 Placebo § n= 6, 108 Endpoints (follow-up mean 3. 4 years): g g Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke www. Clinical trial results. org European Society of Cardiology 2003

EUROPA Trial CV death/non-fatal MI/ cardiac arrest CV Mortality p=0. 107 p=0. 0003 www.

EUROPA Trial CV death/non-fatal MI/ cardiac arrest CV Mortality p=0. 107 p=0. 0003 www. Clinical trial results. org European Society of Cardiology 2003

EUROPA Trial • Among patients with stable coronary artery disease, treatment with the ACE-I

EUROPA Trial • Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo • ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients • The present trial is the largest to show a benefit in stable, lowrisk CAD patients www. Clinical trial results. org